NASDAQ:RETA
Delisted
RETA Stock News
$172.36
+0 (+0%)
At Close: Dec 22, 2023
PLANO, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced
Reata Announces the Appointment of Martin W. Edwards, M.D.
04:05pm, Thursday, 30'th Jul 2020
PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced
Reata Announces Initiation of Investigator-Sponsored Study Evaluating Bardoxolone for Complications Associated with COVID-19
06:45am, Tuesday, 28'th Jul 2020
PLANO, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced
Reata Announces Promotion and New Hires For Key Leadership Roles
06:45am, Tuesday, 07'th Jul 2020
PLANO, Texas, July 07, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced
New York, New York--(Newsfile Corp. - July 3, 2020) - Levi & Korsinsky announces it has commenced an investigation of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) concerning possible breaches of fiduc
Reata Pharmaceuticals, Inc. Closes $350 Million Strategic Investment From Blackstone Life Sciences
10:10am, Wednesday, 24'th Jun 2020
PLANO, Texas, June 24, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the receipt
Stock Upgrades: Reata Pharma Shows Rising Relative Strength
06:31pm, Friday, 12'th Jun 2020
Reata Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
The post Stock Upgrades: Reata Pharma Shows Rising Relative Strength appeared first on Investor's
Reata Pharmaceuticals, Inc. and Blackstone Life Sciences Announce $350 Million Strategic Investment
07:30am, Thursday, 11'th Jun 2020
FINANCING WILL ADVANCE BARDOXOLONE AS THE FIRST POTENTIAL THERAPY FOR ALPORT SYNDROME, AS WELL AS CONTINUE DEVELOPMENT FOR OTHER RARE AND SERIOUS FORMS OF CHRONIC KIDNEY DISEASE
Why Is Reata Pharmaceuticals, Inc. (RETA) Down 19.8% Since Last Earnings Report?
11:30am, Wednesday, 10'th Jun 2020
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago.
Reata (RETA) Q1 Earnings Surpass Estimates, Revenues Miss
10:45am, Tuesday, 12'th May 2020
Reata (RETA) reports narrower-than-expected loss but misses revenue estimates for first-quarter 2020. Shares down.
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2020 Results - Earnings Call Transcript
09:14pm, Monday, 11'th May 2020
Reata Pharmaceuticals, Inc. (RETA) CEO Warren Huff on Q1 2020 Results - Earnings Call Transcript
Reata Pharmaceuticals Inc (RETA) Reports Q1 Loss, Lags Revenue Estimates
06:45pm, Monday, 11'th May 2020
Reata Pharmaceuticals Inc (RETA) delivered earnings and revenue surprises of 54.82% and -53.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st
Why Reata (RETA) Stock Might be a Great Pick
09:50am, Tuesday, 07'th Apr 2020
Reata (RETA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Reata Pharmaceuticals Provides Update on the Impact of the COVID-19 Pandemic on Its Clinical Studies and Business Operations
04:05pm, Monday, 30'th Mar 2020
ONGOING TRIALS IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION STOPPED DUE TO HIGH RISK OF COVID-19 TO THESE PATIENTS
Reata Pharmaceuticals, Inc. (RETA) Down 37.8% Since Last Earnings Report: Can It Rebound?
11:30am, Friday, 20'th Mar 2020
Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago.
